Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1371-1380 Newer>

Bio-IT World August 18, 2004 John Russell	Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy.
Bio-IT World August 18, 2004 Salvatore Salamone	Interactive Decision Making SurroMed's core goal is to discover and validate new biomarkers for a broad spectrum of diseases.
Bio-IT World August 18, 2004 Anthony Strattner	The Pursuit of Process Endo Pharmaceuticals made the strategic decision to enter the electronic age of regulatory submissions, though enduring the demands of automating this core business process was eye-opening.
Bio-IT World August 18, 2004 Mark D. Uehling	I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test.
Bio-IT World August 18, 2004 Mark D. Uehling	Master of the EDC Universe An interview with Sylva Collins, global head of advanced clinical systems at Novartis, who in the case of electronic data capture (EDC), proved to the pharmaceutical industry that technology could be transformative in clinical trials.
Bio-IT World August 18, 2004	Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated.
Bio-IT World August 18, 2004 Nancy Weil	Desert Storm High Throughput Genomics' landed a licensing and supply deal with Merck to use their ArrayPlate qNPA (quantitative nuclease protection assay) technology. The deal is the first with Big Pharma that can be publicly revealed.
Job Journal August 15, 2004 Pat Wooten	Rx from an RN: Of course, nothing can substitute for actual on-the-job experience. But there are simple and inexpensive ways to thoroughly research nursing as a profession. Includes links to some useful websites.
The Motley Fool August 17, 2004 Charly Travers	Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector.
BusinessWeek August 30, 2004 Kerry Capell	Animal-Rights Activism Turns Rabid Attacks on drug companies and university labs have Britain's $8 billion biomedical research industry under siege. But will the government's latest plan to combat extremists be enough?
<Older 1371-1380 Newer> Return to current articles.